Stock AnalizInhibrx Biosciences, Inc. INBX
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Inhibrx Biosciences, Inc. (INBX) is a healthcare company listed in the US with a market value of about $1.2B. In fiscal year 2025 it had revenue of $1M and net income of -$140M, a net margin of -10773.5%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -132%.
Score: 0.4 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $1M | — | $2M |
| Net income | -$140M | $1.7B | -$241M |
| Free cash flow | -$130M | -$197M | -$198M |
| EPS (diluted) | $-9.04 | $112.62 | $-20.48 |
| Net margin | -10773.5% | — | -13408.9% |
| ROIC | -92.8% | -234.0% | -68.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $266.67, 220% above the current price; targets range from $230.00 to $325.00; the consensus rating is “none”; expected EPS is $-9.26 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Inhibrx Biosciences pay a dividend?
Not currently.
Is Inhibrx Biosciences a good stock to buy?
We do not give buy or sell advice. Inhibrx Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.